ExoTENPO uniquely enables disease interception at its earliest stage
Chip Diagnostics’ ExoTENPO is the technology showing the most promise to leverage liquid biopsy (blood) in the earliest disease stage, where currently (tissue) biopsies and imaging strategies dominate.
Exosomes – The Key to Unlocking Full Potential of Liquid Biopsies
Exosomes are a promising new biomarker in liquid biopsy. However, due to their small size and abundance, exosomes are difficult to isolate and interpret. Chip Diagnostics’ technology is the solution to this problem.
The Challenge
Tissues from the body, such as that from brain, lungs, or other vital organs, provide information about diseases, but are not easily accessible without invasive strategies such as biopsies.
Exosomes are shed into the blood from patients’ tissues, but have a diameter 100x smaller than a cell. Existing technology in biology can’t effectively handle the size. There is an enormous number of these vesicles in the blood. Capturing them requires sensors and sorters that are both very fast and very small.
Our Solution
Chip Diagnostics developed ExoTENPO to analyze a patient’s blood, from a routine draw in smaller amounts, to find specific vesicles in the blood coming from the tissues where doctors want to diagnose disease.
Chip Diagnostics Platform
Chip Diagnostics developed a microchip that holds millions of nanoscale sorters, which inspect every vesicle in the blood.
We then incorporated a machine learning tool to look for patterns within these vesicles that can accurately classify and categorize patients.
ExoTENPO combines high-throughput nanoscale sorting with machine learning to interpret the wealth of information packaged within exosomes, resulting in high-value, actionable clinical data.
Current Market Situation
- RESOLUTION
Instruments are not available to isolate tissue specific exosomes with high sensitivity and specificity.
- EASE OF USE
Workflows are complex and time consuming.
- CLINICAL VALUE
Data variability / specificity outcomes limit clinical utility of solutions.
ExoTENPO Solution
- RESOLUTION
ExoTENPO precisely isolates only tissue-specific exosomes from complex biological samples.
- EASE OF USE
ExoTENPO is fully compatible with downstream workflows (NGS, PCR, ELISA).
- CLINICAL VALUE
Our demonstrated AI approach drives the highest AUC outcomes in the earliest disease stages.
Current Market Situation
- RESOLUTION
Instruments are not available to isolate tissue specific exosomes with high sensitivity and specificity.
- EASE OF USE
Workflows are complex and time consuming.
- CLINICAL VALUE
Data variability / specificity outcomes limit clinical utility of solutions.
ExoTENPO Solution
- RESOLUTION
ExoTENPO precisely isolates only tissue-specific exosomes from complex biological samples.
- EASE OF USE
ExoTENPO is fully compatible with downstream workflows (NGS, PCR, ELISA).
- CLINICAL VALUE
Our demonstrated AI approach drives the highest AUC outcomes in the earliest disease stages.